Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lesinurad. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 known ✓ | Q96S37 | 19/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.98 |
| ▸ | SLC2A9 | Q9NRM0 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lesinurad SCHEMBL29353441 | 0.99 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL842962 | 0.99 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL11915750 | 0.95 | SLC22A12 (0.92) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL2221210 | 0.90 | SLC22A12 (0.79) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL16500465 | 0.89 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1299832 | 0.89 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4735350 | 0.89 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1299461 | 0.88 | SLC22A12 (0.81) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL1299308 | 0.88 | SLC22A12 (0.81) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL15698391 | 0.88 | SLC22A12 (0.81) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521716-B1 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETATE, AND USES THEREOF | ARDEA BIOSCIENCES INC (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20130345271-A1 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8524754-B2 | Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetate, and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2521716-A2 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETATE, AND USES THEREOF | Ardea Biosciences, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120129903-A1 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2011085009-A2 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETATE, AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345271-A1 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF | SLC10A1, SLC5A1, HSD3B1 | SLC22A12 200/4885CYP2C9 376/4885CYP2C19 246/4885 |
| US-20120129903-A1 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF | SLC10A1, SLC5A1, HSD3B1 | SLC22A12 200/4885CYP2C9 376/4885CYP2C19 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.